8-K: Passage Bio Stockholders Approve Reverse Split Amidst Director Elections and Auditor Ratification

Passage Bio, Inc. announced the outcomes of its 2025 Annual Meeting of Stockholders, including the election of two Class II directors, ratification of KPMG LLP as its independent auditor, and approval for a potential reverse stock split.

Summary

• Passage Bio, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025.
• Stockholders elected Maxine Gowen, Ph.D. and Dolan Sondhi, Ph.D. as Class II directors, each to serve a three-year term expiring at the 2028 Annual Meeting.
• Maxine Gowen received 26,155,123 'For' votes and 9,920,074 'Withheld' votes, with 13,591,783 broker non-votes.
• Dolan Sondhi received 26,312,059 'For' votes and 9,763,138 'Withheld' votes, with 13,591,783 broker non-votes.
• The appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 49,459,847 'For' votes, 70,721 'Against' votes, and 136,412 'Abstaining' votes.
• Stockholders approved a proposal for the Board of Directors to implement, at its discretion, a reverse stock split of outstanding common stock at a ratio between 1-for-5 and 1-for-50.
• The reverse stock split, if implemented, must occur prior to December 31, 2025, and the Board retains the authority to abandon the amendment without further stockholder action.
• The reverse stock split proposal received 47,038,889 'For' votes, 2,324,612 'Against' votes, and 303,479 'Abstaining' votes.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to the necessity of a reverse stock split, which typically indicates underlying stock price weakness, despite the routine nature of other approvals.

Positives

• The election of two Class II directors ensures continuity in the company's governance structure.
• The ratification of KPMG LLP as the independent auditor provides assurance of continued financial oversight and compliance.
• Approval of the reverse stock split provides the Board with a mechanism to potentially increase the per-share trading price, which could help the company maintain its Nasdaq listing.

Negatives

• The need for a reverse stock split typically indicates a low stock price, which can be a negative signal regarding the company's financial health or market perception.
• A reverse stock split does not address the underlying reasons for a low stock price and can sometimes lead to further price declines post-split.

Risks

• The primary risk is the company's low stock price, which necessitates the consideration of a reverse stock split to potentially meet exchange listing requirements.
• There is a risk that a reverse stock split may not effectively increase or sustain the stock price over the long term, potentially leading to further price erosion or delisting concerns.
• The Board's discretion to determine the exact ratio and implement the split, or abandon it, introduces uncertainty for investors regarding the timing and impact of the action.

Future Outlook

The company's Board of Directors has been granted discretion to implement a reverse stock split at a ratio between 1-for-5 and 1-for-50 prior to December 31, 2025, which is a forward-looking action aimed at potentially increasing the per-share trading price.

Industry Context

Reverse stock splits are often utilized by companies, particularly in the biotechnology sector, when their stock price falls below minimum exchange listing requirements. While they can help maintain listing, they do not inherently improve a company's underlying business fundamentals or financial performance. The approval of such a measure suggests the company is addressing its stock price to remain compliant with exchange rules.

Corporate Governance

Stakeholder Impact

• Shareholders will be directly impacted by the reverse stock split, as the number of outstanding shares will decrease and the per-share price will proportionally increase, though the total value of their holdings should remain the same immediately after the split.
• The potential for a higher per-share price could make the stock more attractive to institutional investors and help maintain Nasdaq listing, benefiting all shareholders.

Next Steps

• The Board of Directors will determine the exact ratio for the reverse stock split, if implemented, and may proceed with the amendment to the company's Restated Certificate of Incorporation prior to December 31, 2025.
• The Board retains the authority to abandon the reverse stock split amendment without further stockholder action.

Key Dates

Recommendation

Keywords

Passage Bio, SEC Filing, 8-K, Annual Meeting, Stockholders, Reverse Stock Split, Corporate Governance, Director Election, Auditor Ratification, Nasdaq, Biotechnology, Gene Therapy